Twelve year clinical study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy

C B COOPER, J WATERHOUSE, P HOWARD

From the University Department of Medicine, Royal Hallamshire Hospital, Sheffield

ABSTRACT Patients presenting with chronic obstructive airways disease and hypoxic cor pulmonale were assessed during a period of clinical stability. Seventy two patients (53 male) with a mean age of 60 years were selected for long term oxygen therapy. Mean FEV₁ was 0·78 l and forced vital capacity 1·9 l. The mean arterial oxygen tension (Pao₂) was 6·1 kPa (46 mm Hg) and the mean arterial carbon dioxide tension (Pco₂) 6·9 kPa (52 mm Hg). All patients had a Pao₂ of less than 8·0 kPa (60 mm Hg) and 57 patients had a Pco₂ of more than 6·0 kPa (45 mm Hg). Pulmonary haemodynamics were measured in 45 patients yielding the following mean values: pulmonary artery pressure 28·3 mm Hg; cardiac output 5·9 l min⁻¹; total pulmonary vascular resistance 59·2 kPa l⁻¹ s⁻¹. Oxygen delivery systems, including 23 oxygen concentrators, were installed in the patients’ homes. Flow rates were adjusted to raise Pao₂ to more than 8·0 kPa (60 mm Hg) for at least 15 hours each day and close supervision was maintained. Overall five year survival was 62%, which is better than previously reported for this type of patient; but the 10 year survival was only 26% owing to an observed acceleration in death rate at about this time. Progressive disturbances of the pulmonary circulation were arrested. Mortality was associated with the severity of airflow obstruction, reflecting a continuing pathological process affecting the airways.

Survival is poor in patients with cor pulmonale complicating chronic obstructive airways disease.¹⁻⁵ The benefits of long term oxygen therapy in these patients were examined in the nocturnal oxygen therapy (NOT) trial and the report of the Medical Research Council Working Party (MRC). In the MRC study survival in women appeared to be better than in men, although the female group was small and hence few deaths occurred during the period of follow up. In men the benefit of long term oxygen therapy on survival was not apparent until about 500 days, a delay that has never been adequately explained. The five year survival in men was 42%. The mean duration of follow up in the NOT trial was 19 months. The projected three year survival in the group having continuous oxygen therapy was 63%. Timms et al⁷ have recently reviewed the data from the NOT trial and report that survival up to eight years is related to the fall in mean pulmonary artery pressure during the first six months of long term oxygen therapy. Survival in the group treated with oxygen for 12 hours each day was correlated with pulmonary vascular resistance, but this relationship was not apparent for those having continuous oxygen therapy.

Our centre has a high incidence of cor pulmonale complicating chronic obstructive airways disease,⁸ and we have conducted a study over 12 years in patients given long term oxygen therapy. Now that expansion of domiciliary oxygen prescribing has gained the approval of the Department of Health and Social Security,⁹ it is important to identify those patients who are likely to benefit and to know what length of survival can be expected with this treatment. We have analysed survival and examined the prognostic value of some clinical characteristics.

Methods

The patients presented from 1971 to 1984 with a clinical diagnosis of chronic bronchitis and emphysema. Most were first encountered during an admission to hospital with an acute exacerbation of airflow obstruction associated with respiratory failure and oedema. After recovery they were assessed during
several weeks of clinical stability. Those fulfilling the following criteria were included in the study: (a) FEV₁ less than 50% of predicted normal values; (b) chronic hypoxaemia with an arterial oxygen tension (PaO₂) consistently less than 8·0 kPa (60 mm Hg); and (c) at least one recorded episode of peripheral oedema as evidence of cor pulmonale. Patients unlikely to be compliant with long term oxygen therapy and those whose homes could not be adequately fitted and supplied with oxygen cylinders were excluded.

Physiological measurements were made on at least two occasions before the start of oxygen therapy and included age, height, weight, packed cell volume, FEV₁, forced vital capacity (FVC), lung volumes determined by helium mixing, and carbon monoxide transfer factor (TLCO) determined by the single breath technique. Blood gas tensions were measured while patients were breathing air and after two hours of breathing 30% oxygen. Many patients underwent right heart catheterisation, a balloon tipped flow directed catheter (Swan Ganz) being introduced via an antecubital vein. Mean pulmonary artery pressure was recorded with a transducer (SE Laboratories 648) and cardiac output was calculated by the Fick equation or by the thermal dilution method. Total pulmonary vascular resistance was calculated on the assumption of a left atrial pressure of zero. Pulmonary haemodynamics were measured again after 12–18 months of long term oxygen therapy.

Seventy two patients were included. Twenty two used oxygen concentrators at some stage during the study and the rest were supplied by regular deliveries of G (3600 l) or F (1360 l) size cylinders. A special maintenance and breakdown service ensured an uninterrupted supply of oxygen and those patients using cylinders were taught to change the reducing valves themselves. Oxygen was given by nasal prongs and the flow rate (1·5–2·5 l min⁻¹) was regulated to maintain the PaO₂ at more than 8·0 kPa (60 mm Hg) during treatment. Patients were instructed to use the system overnight and for at least 15 hours in every 24 hours. Close supervision of patients is necessary to achieve the best compliance; so the patients were reassessed in hospital every three months and monitored by home visits during the intervals. Serial blood gas tensions were measured every two to three months, in hospital and at home, to confirm that the response to treatment was maintained.

Oedema was controlled by diuretic treatment, fluctuations of chronic obstructive airways disease were treated with β₂ sympathomimetic bronchodilators and occasionally with sustained release methylxanthesines. Infections were usually treated with ampicillin or amoxycillin. All patients were discouraged from smoking during the study but it was clear from carboxyhaemoglobin measurements that some continued to do so. The amount smoked by individual patients could not be accurately assessed and it was not possible to make a reliable separation of patients into smokers and non-smokers for the purpose of further analysis. We were unable to determine the direct influence of smoking on survival.

The recruitment of patients was evenly distributed throughout the study and the median duration of follow up was 5 years. Life tables were derived from fitting Cox’s proportional hazards model. Subgroup survival was compared using the Lee Desu statistic. Association of clinical characteristics with survival was examined by the χ² likelihood ratio test. A p value less than 0·05 was considered significant.

### Results

Since 1971 in Sheffield 72 patients (53 men and 19 women) have received domiciliary oxygen therapy according to the selection criteria. Thirty five reported that they were ex-smokers and 37 admitted that they continued to smoke. Their clinical characteristics are shown in table 1. While they were breathing oxygen (inspired oxygen concentration 30%) the mean PaO₂ increased from 6·1 to 9·1 kPa (a mean increase of 3·0 kPa) while the mean arterial carbon dioxide tension (PaCO₂) increased from 6·9 to 7·3 kPa (a mean increase of 0·39 kPa) (table 1). Repeated testing in hospital and at home gives convincing evidence of a sustained increase in PaO₂ in patients having domiciliary oxygen therapy.

Pulmonary artery catheterisation was carried out in 45 patients before entry into the study and was repeated in 40 patients after 12 months of long term oxygen therapy. The values for pulmonary artery

### Table 1

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value (mean ± standard deviation)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y)</td>
<td>60·5 (7·5)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>68·5 (15·0)</td>
</tr>
<tr>
<td>FEV₁ (l)</td>
<td>0·78 (0·31)</td>
</tr>
<tr>
<td>% Pred FEV₁</td>
<td>29 (10)</td>
</tr>
<tr>
<td>FVC (l)</td>
<td>1·90 (0·64)</td>
</tr>
<tr>
<td>TLC (l)</td>
<td>5·65 (1·36)</td>
</tr>
<tr>
<td>RV/TLC (%)</td>
<td>60 (10)</td>
</tr>
<tr>
<td>TLCO (mmol min⁻¹ kPa⁻¹)</td>
<td>3·48 (1·87)</td>
</tr>
<tr>
<td>PaO₂ (air) (kPa)</td>
<td>6·1 (1·0)</td>
</tr>
<tr>
<td>PaCO₂ (air) (kPa)</td>
<td>6·9 (1·2)</td>
</tr>
<tr>
<td>PaO₂ (O₂) (kPa)</td>
<td>9·1 (1·4)</td>
</tr>
<tr>
<td>PaCO₂ (O₂) (kPa)</td>
<td>7·3 (1·4)</td>
</tr>
<tr>
<td>PCV (%)</td>
<td>52 (7)</td>
</tr>
</tbody>
</table>

Conversion: SI to traditional units—Gas tensions: 1 kPa = 7·5 mm Hg; TLCO: 1 mmol min⁻¹ kPa⁻¹ = 2·99 ml min⁻¹ mm Hg⁻¹

FVC—forced vital capacity; TLC—total lung capacity; RV—residual volume; TLCO—carbon monoxide transfer factor; PaO₂—arterial oxygen tension; PaCO₂—arterial carbon dioxide tension; (air)—breathing air; (O₂)—breathing oxygen; PCV—packed cell volume.
Twelve year study of patients with hypoxic cor pulmonale given long term domiciliary oxygen therapy

Table 2. Pulmonary haemodynamics (mean values with standard deviations in parentheses)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Before treatment</th>
<th>After 12 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>PAP (mm Hg)</td>
<td>28.3(10.2)</td>
<td>26.1(11.0)</td>
</tr>
<tr>
<td>(n = 45)</td>
<td>(n = 40)</td>
<td></td>
</tr>
<tr>
<td>Cardiac output (l min⁻¹)</td>
<td>5.9(1.8)</td>
<td>6.7(2.8)</td>
</tr>
<tr>
<td>(n = 42)</td>
<td>(n = 37)</td>
<td></td>
</tr>
<tr>
<td>TPVR (kPa 1⁻¹ s)</td>
<td>59.2(25.3)</td>
<td>51.1(24.7)</td>
</tr>
<tr>
<td>(n = 42)</td>
<td>(n = 37)</td>
<td></td>
</tr>
</tbody>
</table>

Conversion: SI to traditional units—TPVR: 1 kPa 1⁻¹ s = 6.809 dynes cm⁻⁵.
PAP—mean pulmonary arterial pressure; TPVR—total pulmonary vascular resistance.

pressure, cardiac output, and total pulmonary vascular resistance were unchanged (table 2).

The cumulative survival proportions for the whole group of patients are shown in figure 1. The survival proportions for normal subjects and untreated men in the MRC study⁵ have been plotted for comparison. The five year survival proportions for the three groups are 62% (patients in this study), 87% (normal subjects), and 16% (MRC controls). The survival curves suggest that the benefit of long term oxygen therapy follows the start of treatment immediately. The 10 year survival for the patients was 26%, indicating an acceleration in death rate at 10 years despite long term oxygen therapy. Thirty eight had died at the time of analysis (30 men, eight women).

Survival for males and females is plotted separately in figure 2. There was no difference in survival between the sexes (p = 0.583) and the survival curves lie between those of the treated male and female groups of the MRC study.

The association of various clinical characteristics with survival was analysed with a χ² likelihood ratio test (table 3). Survival was clearly associated with indices of airflow obstruction (FEV₁; p = 0.019; FVC: p = 0.013), whereas no association was observed with blood gas tensions during the breathing of air, the rise in Pao₂ during the breathing of oxygen, pulmonary artery pressure or total pulmonary vascular resistance. When subgroups were compared, sur-

Table 3. Association of clinical characteristics at entry with survival of patients having long term oxygen therapy

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>χ²*</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.213</td>
<td>0.271</td>
</tr>
<tr>
<td>FEV₁</td>
<td>5.551</td>
<td>0.019</td>
</tr>
<tr>
<td>% Pred FEV₁</td>
<td>5.167</td>
<td>0.023</td>
</tr>
<tr>
<td>FVC</td>
<td>6.112</td>
<td>0.013</td>
</tr>
<tr>
<td>PaO₂ (air)</td>
<td>1.217</td>
<td>0.270</td>
</tr>
<tr>
<td>PaCO₂ (air)</td>
<td>0.386</td>
<td>0.534</td>
</tr>
<tr>
<td>Pao₂ (O₂)</td>
<td>1.155</td>
<td>0.283</td>
</tr>
<tr>
<td>PaO₂ (O₂)</td>
<td>2.400</td>
<td>0.122</td>
</tr>
<tr>
<td>dPaO₂</td>
<td>0.004</td>
<td>0.953</td>
</tr>
<tr>
<td>PAP</td>
<td>1.578</td>
<td>0.209</td>
</tr>
<tr>
<td>TPVR</td>
<td>1.423</td>
<td>0.233</td>
</tr>
</tbody>
</table>

* Likelihood ratio test from fitting Cox's proportional hazards model. FVC—forced vital capacity; Pao₂—arterial oxygen tension; PaCO₂—arterial carbon dioxide tension; PaO₂—arterial oxygen tension; PAP—mean pulmonary artery pressure; TPVR—total pulmonary vascular resistance.

Fig 1. Life table for all patients having long term oxygen therapy. The predicted survival proportions for an exactly age and sex matched group of normal individuals have been derived from the English Life Table 1970–72.¹ The survival of untreated men in the Medical Research Council study has been plotted by use of the calculated annual risk factor 29.4%.⁵

Fig 2. Life tables for patients having long term oxygen therapy according to sex, showing no difference in survival between men (—) and women (---). Survival curves of treated male and female groups in the Medical Research Council study are plotted for comparison.
Survival was worse in patients with an FEV₁ below 30% predicted (p = 0.029), as shown in figure 3, but not significantly different in those with a pulmonary artery pressure greater than 25 mm Hg or a total pulmonary vascular resistance greater than 58.8 kPa⁻¹ s (400 dynes s cm⁻⁵).

Discussion

The patients in this study form a carefully selected group with severe airflow obstruction, hyperinflation, arterial hypoxaemia at rest, and impairment of gas transfer. All had experienced acute episodes of cor pulmonale. They entered the study in a stable hypoxaemic state, 57 remaining hypercapnic (Paco₂ > 6.0 kPa).

Survival is considerably better than has previously been reported for hypoxic cor pulmonale in patients with similar degrees of airflow obstruction, hypoxia, and pulmonary hypertension (table 4). The five year survival without treatment is less than 40%.¹⁻⁵ In a study of patients with hypoxic cor pulmonale given continuous oxygen therapy two year survival was 72%.¹⁴ The predicted five year survival proportions for treated patients in the MRC and NOT trials were 53% (11.9% annual risk) and 39% (17.2% annual risk overall). These figures compare with a five year survival in the present study of 62% (8.8% annual risk) and a 10 year survival of 26%. The five year survival for an age and sex matched group of normal individuals is 87% according to English Life Tables 1970–1972.¹⁵ A selected group of patients with hypoxic cor pulmonale and oedema associated with chronic bronchitis and emphysema can expect a doubling of survival time as a result of long term oxygen therapy given for at least 15 hours each day. This conclusion is based on retrospective comparisons and therefore must be interpreted with caution. A change in the nature of the disease or general improvement in management of the patients may have contributed to the fall in mortality that we observed. Nevertheless, these are the best survival figures so far reported in hypoxic cor pulmonale and provide justification for selecting this type of patient for long term oxygen therapy.

There are discrepancies with the results of the MRC study,¹³ which had similar patients. Five hundred days elapsed before benefit was apparent in men and this delay has never been explained. Our findings suggest, however, that the benefit of long term oxygen therapy is immediate, but clearly large numbers of patients and controls would be required to prove a significant difference in survival early after the start of oxygen therapy. The greater number of female patients has
eliminated the apparent difference in survival between
the sexes and emphasises that the female survival
curve accompanies that of the males.

A 10 year survival of only 26% is disappointing and
probably relates to a continuing pathological process
that exerts its effect on airway function rather than in
the pulmonary circulation. Survival for patients hav-
ing long term oxygen therapy was clearly associated
with indices of airflow obstruction but not with pul-
monary artery pressure or total pulmonary vascular
resistance. The prognostic value of FEV$_1$ is recog-
nised from large studies of patients with chronic
obstructive Airways disease and when FEV$_1$
falls below 450 ml it contributes significantly to a poor
prognosis. In severe hypoxic cor pulmonale without
oxygen therapy progressive pulmonary hypertension
becomes an important determinant of mortal-
ty, and this may mask the relationship
between FEV$_1$ and survival. Acute administration
of oxygen lowers pulmonary artery pressure and a fall
greater than 5 mm Hg has been associated with better
survival for patients having long term oxygen ther-
apy. The fall in pulmonary artery pressure can be
sustained with long term oxygen therapy. In this
study pulmonary artery pressure and total pulmonary
vascular resistance were unchanged at the end of the
first year of treatment in those who had haemo-
dynamic measurements at this time and stabilisation
of pulmonary artery pressure and total pulmonary
vascular resistance was confirmed in some patients up
to six years later. Long term oxygen therapy appears
to interrupt the progression of haemodynamic dis-
turbances, as was also observed in the MRC study,
and in doing so has displaced the correlation of pul-
monary hypertension with mortality.

There are two possible explanations. Long term
oxygen therapy may prevent death from disturbances
of the pulmonary circulation, so that mortality is then
related to the continuing disease process in the air-
ways and lung parenchyma. Alternatively, it is possi-
ble that the correlation of mortality with pulmonary
hypertension is spurious, only masking important
pathophysiological events elsewhere. The relevance of
pulmonary hypertension has always been in doubt
since the pulmonary artery pressure in chronic
obstructive Airways disease is usually considerably
lower than in primary pulmonary hypertension,
where right ventricular afterload leads to a fall in
cardiac output to very low values. In hypoxic cor
pulmonale cardiac output remains normal or is
raised and right ventricular function is only marginally impaired. Failure to adapt by an
increase in cardiac output leads to a reduction in oxygen delivery to the tissues and a fall in mixed venous
oxygen tension, which has been associated with a poor
survival rate. Unfortunately the beneficial effect of
oxygen may be counterbalanced by a fall in cardiac
output, so that oxygen delivery remains unchanged.
Generally the measurement of pulmonary artery pres-
sure in chronic obstructive Airways disease is unhelpful but a detailed pathophysiological study of
the Airways and pulmonary circulation is needed in
patients having long term oxygen therapy.

This study confirms that long term oxygen therapy
is of benefit in carefully selected patients with hypoxic
chronic obstructive Airways disease. It is not yet clear
whether it improves survival in hypoxic patients with-
out oedema or in those with other forms of chronic
respiratory disease. The analysis shows that there is
no relationship between initial blood gas tensions and
survival when hypoxia is subsequently corrected by
long term oxygen therapy. Twenty nine of the 57
patients who were hypercapnic (PaCO$_2$ greater than
6-0 kPa (45 mm Hg)) at entry died during the study but
only three of the 15 normocapnic patients died. This
suggests that chronic hypercapnia is associated with a poorer prognosis even though the five year survival in
this subgroup was 59%. Survival was better in patients who started long term oxygen therapy within
the first year of treatment. In those who had haemo-
dynamic measurements at this time and stabilisation
of pulmonary artery pressure and total pulmonary
vascular resistance was confirmed in some patients up
to six years later. Long term oxygen therapy appears
to interrupt the progression of haemodynamic dis-
turbances, as was also observed in the MRC study,
and in doing so has displaced the correlation of pul-
monary hypertension with mortality.

We thank Dr J P Nicholl for assisting with the statis-
tical analysis and the staff of the respiratory function
unit who have been concerned with the assessment of
the patients.

References

1 Stuart-Harris CH, Hanley T. Chronic bronchitis,
emphysema and cor pulmonale. Bristol: John Wright
and Sons, 1957.

2 Boushy SF, Coates EO jun. The prognostic value
of pulmonary function tests in emphysema: with special
reference to arterial blood studies. Am Rev Respir Dis
1964;90:553–63.

3 Renzetti AD, McClement JH, Litt BD. The Veterans
Administration Cooperative Study of Pulmonary
Function III. Mortality in relation to respiratory func-
tion in chronic obstructive pulmonary disease. Am J